Form 4: Madryn Sells $13M STIM Shares

Madryn Asset Management, a 10% owner and director of Neuronetics, Inc., reported the sale of 3.5 million shares of common stock for approximately $13 million, executed under a pre-planned trading arrangement.

Summary

• Madryn Asset Management, LP, along with affiliated entities, a 10% owner and director of Neuronetics, Inc. (STIM), reported the sale of 3,500,000 shares of STIM common stock.
• The shares were sold at a price of $3.72 per share.
• The total value of the shares sold amounts to approximately $13,020,000.
• The transaction occurred on August 8, 2025, and was made pursuant to a Rule 10b5-1(c) trading plan.
• Following these transactions, Madryn and its affiliates beneficially own a total of 20,737,061 shares of Neuronetics common stock indirectly.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant insider sale by a 10% owner and director. While the 10b5-1 plan suggests it was pre-planned, the sheer volume of shares sold (3.5 million) at $3.72 per share still indicates a reduction in exposure by a key stakeholder, which can weigh on investor confidence.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, indicating a pre-scheduled transaction rather than an immediate reaction to new, adverse information.

Negatives

• A significant sale of 3.5 million shares by a 10% owner and director, Madryn Asset Management, could be perceived negatively by the market, signaling a reduction in conviction or a need for liquidity.
• The sale price of $3.72 per share indicates the price at which the insider chose to divest a substantial portion of their holdings.

Risks

• Significant insider selling, especially by a large institutional holder and director, can signal a lack of confidence in the company's future prospects or valuation, potentially leading to negative market sentiment and downward pressure on the stock price.
• The large volume of shares sold could increase the floating supply of shares, potentially impacting market liquidity and price stability.

Future Outlook

The filing does not provide forward-looking statements or guidance regarding Neuronetics, Inc.'s future performance or strategic direction. It solely reports a past insider transaction.

Industry Context

Insider selling by a significant institutional investor and director in the medical device or neuroscience sector can sometimes be interpreted as a signal regarding the company's near-term prospects or the broader industry's valuation. However, given the transaction was under a 10b5-1 plan, it may reflect pre-determined portfolio rebalancing rather than a new negative outlook on Neuronetics specifically.

Comparison to Industry Standards

• A sale of this magnitude by a 10% owner is a notable event. While not directly comparable to specific company projects or results, such insider sales are typically scrutinized by investors.
• In the broader market, large insider sales can sometimes precede periods of underperformance for the stock, though the presence of a 10b5-1 plan mitigates the immediate negative signaling effect compared to an unplanned sale.

Management Changes

Corporate Governance

Legal Proceedings

• The filing does not mention any legal proceedings or regulatory matters.

Related Party Transactions

• The reported sale of 3,500,000 shares of Neuronetics, Inc. common stock by Madryn Asset Management, LP and its affiliated entities constitutes a related party transaction, as these entities are identified as a 10% owner and director of the issuer.

Stakeholder Impact

• Shareholders may interpret the significant insider sale as a signal of reduced confidence from a major investor, potentially leading to downward pressure on the stock price.
• The transaction itself does not directly impact employees, customers, suppliers, or creditors, but market reaction could indirectly affect company morale or perception.

Next Steps

• The filing does not outline any specific future actions, events, or milestones for Neuronetics, Inc. or the reporting persons beyond the reported transaction.

Key Dates

Recommendation

While a significant insider sale by a 10% owner and director is generally a negative signal, the fact that it was executed under a Rule 10b5-1(c) plan suggests it was a pre-scheduled divestment rather than a reaction to new, adverse information. This mitigates the immediate 'sell' signal. However, the sheer volume of shares sold (3.5 million) at $3.72 per share by a major stakeholder warrants caution. Investors should 'hold' to observe market reaction and await further company-specific news or financial reports that could provide more context on the company's performance and outlook, rather than making an immediate 'sell' decision based solely on this pre-planned insider transaction.

Keywords

Neuronetics, STIM, Madryn Asset Management, Insider Sale, Form 4, SEC Filing, Stock Sale, 10b5-1 Plan, Medical Devices, Neuroscience